These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 27346381

  • 1. Decreased serum bone specific alkaline phosphatase and increased urinary N-terminal telopeptide of type I collagen as prognostic markers for bone mineral density loss in HIV patients on cART.
    Koga I, Seo K, Yoshino Y, Kitazawa T, Kurahashi I, Ota Y.
    J Infect Chemother; 2016 Aug; 22(8):543-7. PubMed ID: 27346381
    [Abstract] [Full Text] [Related]

  • 2. Bone mineral density changes after 2 years of ARV treatment, compared to naive HIV-1-infected patients not on HAART.
    Rey D, Treger M, Sibilia J, Priester M, Bernard-Henry C, Cheneau C, Javier RM.
    Infect Dis (Lond); 2015 Feb; 47(2):88-95. PubMed ID: 25426996
    [Abstract] [Full Text] [Related]

  • 3. Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization.
    Colao A, Di Somma C, Loche S, Di Sarno A, Klain M, Pivonello R, Pietrosante M, Salvatore M, Lombardi G.
    Clin Endocrinol (Oxf); 2000 Mar; 52(3):319-27. PubMed ID: 10718830
    [Abstract] [Full Text] [Related]

  • 4. Abatacept might increase bone mineral density at femoral neck for patients with rheumatoid arthritis in clinical practice: AIRTIGHT study.
    Tada M, Inui K, Sugioka Y, Mamoto K, Okano T, Koike T.
    Rheumatol Int; 2018 May; 38(5):777-784. PubMed ID: 29294175
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Correlation of different bone markers with bone density in patients with rheumatic diseases on glucocorticoid therapy.
    Loddenkemper K, Bohl N, Perka C, Burmester GR, Buttgereit F.
    Rheumatol Int; 2006 Feb; 26(4):331-6. PubMed ID: 15887044
    [Abstract] [Full Text] [Related]

  • 7. Predictive factors of change in BMD at 1 and 2 years in women with anorexia nervosa: a study of 146 cases.
    Legroux-Gérot I, Vignau J, d'Herbomez M, Flipo RM, Cortet B.
    Osteoporos Int; 2012 Dec; 23(12):2855-61. PubMed ID: 22349911
    [Abstract] [Full Text] [Related]

  • 8. Increased urinary N-telopeptide cross-linked type 1 collagen predicts bone loss in patients with inflammatory bowel disease.
    Dresner-Pollak R, Karmeli F, Eliakim R, Ackerman Z, Rachmilewitz D.
    Am J Gastroenterol; 2000 Mar; 95(3):699-704. PubMed ID: 10710060
    [Abstract] [Full Text] [Related]

  • 9. Vitamin D and Calcium Addition during Denosumab Therapy over a Period of Four Years Significantly Improves Lumbar Bone Mineral Density in Japanese Osteoporosis Patients.
    Suzuki T, Nakamura Y, Kato H.
    Nutrients; 2018 Feb 27; 10(3):. PubMed ID: 29495518
    [Abstract] [Full Text] [Related]

  • 10. Bone turnover markers in the preoperative assessment of bone quality - A prospective investigation of bone microstructure and advanced glycation endproducts in lumbar fusion patients.
    Haffer H, Muellner M, Chiapparelli E, Zhu J, Han YX, Donnelly E, Shue J, Hughes AP.
    Arch Orthop Trauma Surg; 2024 Aug 27; 144(8):3291-3301. PubMed ID: 39105842
    [Abstract] [Full Text] [Related]

  • 11. Detection of post-menopausal women with low bone mineral density and elevated biochemical markers of bone turnover by panoramic radiographs.
    Taguchi A, Ohtsuka M, Nakamoto T, Suei Y, Kudo Y, Tanimoto K, Bollen AM.
    Dentomaxillofac Radiol; 2008 Dec 27; 37(8):433-7. PubMed ID: 19033427
    [Abstract] [Full Text] [Related]

  • 12. Differences of therapeutic effects on regional bone mineral density and markers of bone mineral metabolism between alendronate and alfacalcidol in Japanese osteoporotic women.
    Takata S, Abbaspour A, Yonezu H, Yasui N.
    J Med Invest; 2007 Feb 27; 54(1-2):35-40. PubMed ID: 17380012
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Interruption or deferral of antiretroviral therapy reduces markers of bone turnover compared with continuous therapy: The SMART body composition substudy.
    Hoy J, Grund B, Roediger M, Ensrud KE, Brar I, Colebunders R, Castro ND, Johnson M, Sharma A, Carr A, INSIGHT SMART Body Composition Substudy Group.
    J Bone Miner Res; 2013 Jun 27; 28(6):1264-74. PubMed ID: 23299909
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Secondary osteoporosis in liver transplant recipients: a longitudinal study in patients with and without cholestatic liver disease.
    Bjøro K, Brandsaeter B, Wiencke K, Bjøro T, Godang K, Bollerslev J, Schrumpf E.
    Scand J Gastroenterol; 2003 Mar 27; 38(3):320-7. PubMed ID: 12737449
    [Abstract] [Full Text] [Related]

  • 19. Factors associated with low bone mass in the hemodialysis patients--a cross-sectional correlation study.
    Huang GS, Chu TS, Lou MF, Hwang SL, Yang RS.
    BMC Musculoskelet Disord; 2009 Jun 04; 10():60. PubMed ID: 19497099
    [Abstract] [Full Text] [Related]

  • 20. Experience with alendronate treatment for 7 years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures.
    Iwamoto J, Uzawa M.
    Clin Rheumatol; 2016 Jan 04; 35(1):205-12. PubMed ID: 25367347
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.